Company intelligence / Profile preview

Inthera Bioscience AG

Zurich, Zurich, Switzerlandswissbiotech.org ↗

Ownership: Private
Development stage: Preclinical

Overview

Inthera Bioscience’s lead molecule, INTH‑454, is a new chemical entity that inhibits DNA replication and cell cycle control in tumor cells. It is currently in late preclinical development and has shown efficacy against cancer cells with high proliferation rates. The company’s approach merges the versatility of small molecules with the specificity of biologics to target previously “undruggable” intracellular targets relevant to oncology. No clinical results have been published yet as programs are not yet in human trials

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

INTH-454

Preclinical

Partnerships

M Ventures (investor/partner)No major pharma partnerships publicly disclosed.

Beyond the preview

Go deeper on Inthera Bioscience AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inthera Bioscience AG.

Explore the full profile